|
 |
 Home > Available Issues |
|
|
 Original Articles |
| In Vitro antimicrobial Activity of Pristinamycin(Pyostacine®)against Methicillin-Resistant Staphylococcus aureus, Penicillin-Resistant Streptococcus pneumoniae and Haemophilus influenza Clinical isolates |
| Cheong-Won Park, Jeon-Young Song, Chui-Hyun Kim, Hee-Jin Cheong, Woo-Joo Kim, Min-Ja Kim, and Seung-Chull Park |
| Department of Internal Medicine, Korea University Medical College |
Vol.18 Num.4 (p391~400)
|
|
|
Background : Pristinamycin(Pyostaine®) is a natural antibacterial combination of compounds produced by Streptomyces pristinaespiralis. It has been marketed in European countries over 30 years as an oral, anti-staphylococal agent. Because of the increasing prevalence of microorganisms that are resistant to multiple antimicrobial agents in Korea, there are demand of noble antibiotics like pristinamycin against these resistant organisms.
Methods : The one-hundred and fifty bacterial strains which were collected from Korea University. Guro hospital included sixty methicillin-resistant S. aureus (MRSA), fifty penicillin-resistant S. pneumoniae (PRSP) and forty H. influenza clinical isolates. Using an microbroth dilution or agar dilution technique, we compared the antimicrobial activities of pristinamycin and other usual antibiotics against the study microorganisms.
Results : All of sixty MRSA strains were multiply resistant to other antimicrobial agents, but 100% of MRSA strains were susceptible to pristinamycin (MIC range : 0.125-1mg/L). All of fifty PRSP strains were multiple resistant to other antimicrobial agents, but 100% of PRSP strains were susceptible to pristinamycin (MIC range: 0.125-1mg/L). Twenty-seven strains of forty H. influenza strains were β-lactamase positive, and 95%(38/40) of H. influenza strains were susceptible to prisitinamycin (MIC rage : 0.015-4mg/L).
Conclusion : Pristinamycin demonstrated the highly active, in vitro antimicrobial activities against MRSA, PRSP, and H. influenza isolates, so it might be an effective oral therapeutic agent for treating patients with mild infection due to those organisms or on the outpatient setting.
|
|
|
Keywords : Pristinamycin(Pyostacine®), Methicillin-resistant S. aureus, Penicillin-resistant S. pneumoniae, H, influenza |
|
|
|
|
|
|
|
|
